Both organizations working together to form a commercial partnership to launch ImaginAb’s CD8 ImmunoPET technology into the Greater China market
Los Angeles (USA) and Yantai (China) – January 26th, 2022. ImaginAb, a market leading global biotechnology company, focused on developing next generation immuno-oncology imaging agents and therapeutic radiopharmaceuticals (RPT), is pleased to announce it is working with DongCheng Pharmaceutical Group, to form a commercial partnership to bring ImaginAb’s CD8 ImmunoPET agent, zirconium Zr 89 crefmirlimab berdoxam product, into the Greater China market. While zirconium Zr 89 crefmirlimab berdoxam will be initially used in third party sponsored clinical trials, the goal will be to achieve market authorization.
ImaginAb CEO, Ian A Wilson stated: “ImaginAb aim to be a leading global imaging and radiotherapy company, and as such, China is an important market for our products. We are pleased to be working with DongCheng to deliver our diagnostic imaging to cancer patients in China.
Our aim is to form a commercial partnership that will see us deliver our CD8 ImmunoPET agent to cancer patients in China. With DongCheng’s vast experience in molecular imaging, they possess the technical experience and execution infrastructure to be an ideal clinical and commercial partner for ImaginAb in China.”
DongCheng Pharmaceutical Group CEO, Grant Luo stated: “By partnering with ImaginAb, we are expected to bring in an ImmunoPET tracer to visualize cytotoxic CD8+ T cells in the tumor microenvironment, which may help accurately select and monitor the appropriate population receiving immune checkpoint inhibitor treatment and further promote the effectiveness of immunotherapy treatments.
We also hope to cooperate with clinical experts and pharmaceutical companies through our nationwide GMP nuclear pharmacies network, to help accelerate the clinical development and commercial launch of novel therapeutics with high clinical benefits and to address the patients’ needs.”
On signing of a definitive agreement, ImaginAb will receive a license fee and will be entitled to receive potential milestone payments and up to double digit royalties for the CD8 ImmunoPET License and Commercial Partnership for Greater China Market. No other terms were disclosed.